Gilead Sciences Inc. has described GTPase KRAS inhibitors, particularly wild-type KRAS, KRAS (G12C mutant), KRAS (G12D mutant) and/or KRAS (G12V mutant) inhibitors, found to be potentially useful for the treatment of cancer.
Valerio Therapeutics SA has entered into a binding term-sheet with Abivax SA setting out the principal terms of an exclusive worldwide research and development collaboration to identify, design and evaluate next-generation therapeutic candidates for immune-mediated inflammatory diseases.
Abbott Laboratories raised its full-year 2026 adjusted diluted adjusted earnings per share guidance to $5.45 to $5.60, from previous range of $5.38 to $5.58, after a strong performance in the second quarter. Growth was driven by its medical devices business and cancer diagnostic unit.
Advancell Co. Ltd. has raised an oversubscribed $315 million series D round to accelerate its push to become a fully integrated global radiopharma developer, funding late-stage clinical development alongside isotope supply and manufacturing infrastructure.
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization.
Work at Shouyao Holdings (Beijing) Co. Ltd. has led to the identification of new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer.
Cimplrx Co. Ltd. and Dong Wha Pharmaceutical Co. Ltd. have discovered new carboxamide derivatives acting as interleukin-1 receptor-associated kinase 4 (IRAK-4) and/or IRAK-1 inhibitors. As such, they are potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Genesis Molecular AI Inc. has synthesized new phosphatidylinositol 3-kinase α (PI3Kα) (mutant) inhibitors potentially useful for the treatment of cancer.
Tyra Biosciences Inc. has patented new pyrazolopyridine and imidazopyridine derivatives acting as fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer.
RSS
